DCM
KBIO

DAFNA Capital Management’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

DAFNA Capital Management’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-31,250
Closed -$1.13M – 58
2013
Q3 		$1.13M Buy
31,250
+21,271
+213% +$969K 1.23% 20
2013
Q2 		$452K Buy
+9,979
New +$452K 0.66% 34

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
LBH
Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DAFNA Capital Management's KBIO Position: Q4 2013 in Review

DAFNA Capital Management sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2013, closing a stake of 31,250 shares — an estimated $1.13M sold.

DAFNA Capital Management first reported a position in KBIO in Q2 2013 and held it in 2 quarters. The position peaked at $1.13M in Q3 2013. 46 funds tracked by Wall St. Rank hold KBIO as of Q4 2013.

  • DAFNA Capital Management reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2013 after selling out during the quarter.
  • DAFNA Capital Management sold 31,250 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2013, an estimated $1.13M.
  • DAFNA Capital Management first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 2 quarters.
  • DAFNA Capital Management's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $1.13M in Q3 2013.
  • 46 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2013.

Based on DAFNA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.